Лекарственное лечение метастазов тройного негативного рака молочной железы О. В. Смирнова , 2, В. И. Борисов 1, Л. З. Вельшер 1 гбуз «Онкологический клинический диспансер №1»

Cancer Res Treat.
2012;133(3):1067-1075.
doi:10.1007/s10549-012-2008-6.
57. Cortes J, O`Shaughnessy J, Loesch D et al. Eribulin monotherapy 
versus treatment of physician’s choice in patients with metastatic 
breast cancer (EMBRACE): a phase 3 open-label randomized 
study. Lancet. 2011;377(9769):914-923.
doi:10.1016/s0140-6736(11)60070-6.
58. Yardley DA, Richards PD, Reeves JA et al. Final results
of a phase 2 study of ramucirumab (RAM) plus eribulin (E) 
versus E in advanced metastatic breast cancer (MBC). 
J Clin Oncol. 
2014;32(5,Suppl.):abstr.1035. (ASCO Annual 
Meeting). 
59. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone 
(BMS-247550) in a phase II study of patients with advanced breast 
cancer resistant to an anthracycline, a taxane, and capecitabine. J 
Clin Oncol
. 2007;25(23):3407-3413.
doi:10.1200/jco.2006.09.3849.
60. Thomas, ES, Gomez HL, Li RK. Ixabepilone plus capecitabine 
for metastatic breast cancer progressing after anthracycline and 
taxane treatment. J Clin Oncol. 2007;25(33):5210-5217.
doi:10.1200/jco.2007.12.6557.
61. Curigliano G, Pivot X, Cortes J et al. Randomized phase II study 
of sunitinib versus standart of care for patients with previously 
treated advanced triple-negative breast cancer. The Breast. 
2013;22(5):650-656.
doi:10.1016/j.breast.2013.07.037.

ОНКОЛОГИЯ. ЖУРНАЛ им. П.А. ГЕРЦЕНА, 6, 2015
82
62. Baselga J, Segalla JG, Roche H et al. Sorafenib in combination 
with capecitabine: an oral regimen for patients with HER2-
negative locally advanced or metastatic breast cancer. J Clin 
Oncol
. 2012;30(13):1484-1491.
doi:10.1200/jco.2011.36.7771.
63. Gradishar WJ, Kaklamani V, Prasad Sahoo T et al. A double-
blind, randomized, placebo-controlled, phase 2b study evaluating 
the efficacy and safety of sorafenib (SOR) in combination with 
paclitaxel (PAC) as a first-line therapy in patients (pts) with 
locally recurrent or metastatic breast cancer (BC). Cancer Res. 
2009;69(24,Suppl.):44.
doi:10.1158/0008-5472.sabcs-09-44.
64. Schwartzberg LS, Tauer KW, Hermann RC et al. Sorafenib or 
placebo with either gemcitabine or capecitabine in patients with 
HER2-negative advanced breast cancer that progressed during of 
after bevacizumab. Clin Cancer Res. 2013;19(10):2745-2754.
doi:10.1158/1078-0432.ccr-12-3177.
65. Piechocki MP, Wu GS, Jones RF et al. Induction of pro-
apoptotic antibodies to triple negative breast cancer by vac-
cination with TRAIL death receptor DR5 DNA. Int J Cancer. 
2012;131(11):2562-2572.
doi:10.1002/ijc.27534.
66. Malin D, Chen F, Schiller C et al. Enhanced metastasis suppres-
sion by targeting TRAIL receptor 2 in a murine model of triple-
negatgive breast cancer. Clin Cancer Res. 2011;17(15):5005-5015.
doi:10.1158/1078-0432.ccr-11-0099.
67. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active 
small molecule inhibitor of both the src and abl kinases, selectively 
inhibits growth of basal-type/«triple-negative» breast cancer cell 
lines growing in vitro. Breast Cancer Res Treat. 2007;105(3):319-
326.
doi:10.1007/s10549-006-9463-x.
Поступила 22.06.2015
ОБЗОРЫ ЛИТЕРАТУРЫ